Storage and handling
Other information Do not store above 25 0 C or 77 0 F
No7 Lifting and Firming Day Sunscreen SPF 8
- Manufacturer
- BCM Ltd | The Boots Company PLC
- Effective date
- 2010-12-06
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 22:26:33
Label at a glance#
ProductNo7 Lifting and Firming Day Sunscreen SPF 8
Active ingredientOCTINOXATE, AVOBENZONE, OCTISALATE
Label structure16 sections
Contacts and useful links#
Websitewww.boots.com
www.boots.com
www.boots.comLabel contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
No7 Lifting and Firming Day Cream Sunscreen SPF 8
Active ingredients Purpose
Avobenzone (3.0%) SunscreensOctinoxate (7.5%)
Octisalate (2.0%)
OTC - PURPOSE SECTION
Uses
- Provides minimal protection against adverse effects of the sun
- Higher SPF gives more protection
WARNINGS AND PRECAUTIONS SECTION
Warnings
For external use only
When using this product
- Avoid contact with eyes.
- If contact occurs, rinse immediately with cold water.
OTC - ASK DOCTOR SECTION
Stop use and ask a doctor if rash or irritation develops and lasts.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed get medical help.
INDICATIONS & USAGE SECTION
Directions
- After cleansing and toning, massage in small upwards circles onto your face and neck.
STORAGE AND HANDLING SECTION
Other information
Do not store above 250C or 770F
INACTIVE INGREDIENT SECTION
Inactive ingredients
Aqua (Water), Glycerin, C12-15 alkyl benzoate, Dimethicone, Butyrospermum parkii (Shea butter), Polyglyceryl-3 methylglucose distearate, Cetearyl alcohol, VP/hexadecene copolymer, Cyclopentasiloxane, Polyacrylamide, Cyclohexasiloxane, Dimethiconol, C18-36 acid glycol ester, Dipalmitoyl hydroxyproline, C13-14 isoparaffin, Potassium sorbate, Butylene glycol, Methylparaben, Sodium ascorbyl phosphate, Parfum (Fragrance), Ethylparaben, Citric acid, Acrylates/vinyl isodecanoate crosspolymer, Laureth-7, Tetrasodium EDTA, Potassium hydroxide, Haematococcus pluvialis powder, Lupinus albus seed extract, Carbomer, Polysorbate 20, BHT, Polyglucuronic acid, Phenoxyethanol, Butylparaben, Propylparaben, Isobutylparaben, Palmitoyl oligopeptide, Palmitoyl tetrapeptide-7
OTC - QUESTIONS SECTION
USA: Questions? 1-866-75-BOOTS
INFORMATION FOR PATIENTS SECTION
Made in the UK
The Boots Company PLC Nottingham England NG2 3AA
Dist in the USA by Boots Retail USA Inc. Stamford CT 06901 USA
DESCRIPTION SECTION
Love the feeling...
Firm, hydrate and redefine your skin with this incredibly powerful day cream. It works to lift and firm as soon as you smooth it on, measurably reducing the appearance of lines and wrinkles. Your skin tone will appear more even, revealing younger looking skin in just 2 weeks.
We've blended an energizing complex with rich, feel-good moisturisers to smooth your skin and boost your natural radiance. At the same time, SPF 8 protects your skin from the sun.
A little facial every day...
After cleansing and toning, massage in small upwards circles over your face and neck.
You'll get even better results if you use Lifting and Firming Night Cream at bedtime as well.
Keep away from eyes and fabrics.
Dermatologically tested.
www.boots.com
Firm, hydrate and redefine your skin with this incredibly powerful day cream. It works to lift and firm as soon as you smooth it on, measurably reducing the appearance of lines and wrinkles. Your skin tone will appear more even, revealing younger looking skin in just 2 weeks.
We've blended an energizing complex with rich, feel-good moisturisers to smooth your skin and boost your natural radiance. At the same time, SPF 8 protects your skin from the sun.
A little facial every day...
After cleansing and toning, massage in small upwards circles over your face and neck.
You'll get even better results if you use Lifting and Firming Night Cream at bedtime as well.
Keep away from eyes and fabrics.
Dermatologically tested.
www.boots.comDESCRIPTION SECTION
Jar label
Massage onto clean skin daily, avoiding eyes.
Hypo-allergenic.
Dermatologically Tested
Massage onto clean skin daily, avoiding eyes.
Hypo-allergenic.
Dermatologically Tested
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients:
Octinoxate 7.5%
Avobenzone 3%
Octisalate 2%
INFORMATION FOR PATIENTS SECTION
Made in the UK
The Boots Company PLC Nottingham England NG2 3AA
Dist in the USA by Boots Retail USA Inc. Stamford CT 06901 USA
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Carton label
No7 Lifting and Firming Day Cream
Visibly firms and redefines in just 2 weeks
Sunscreen SPF 8
Hypo-allergenic
Boots
50ml e 1.69 US Fl. Oz
Lifting and Firming Day Cream carton.jpg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
No7 Lifting and Firming Day Cream
Sunscreen SPF 8
50ml 1.69 US Fl. Oz
Lifting and Firming Day Cream labels.jpg
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 11489-064-01 | 2019-10-29 | C162847 | 48780-1 | 960f7f55-d535-8e05-e053-dbdaa90a074a | Carton and jar labelling |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 11489-064-01 | No7 Lifting and Firming Day Sunscreen SPF 8 | 50 mL in 1 JAR | EMULSION | 50 | 1 | |
| 11489-064-01 | No7 Lifting and Firming Day Sunscreen SPF 8 | 1 in 1 CARTON | EMULSION | 1 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| AVOBENZONE | ACTIVE INGREDIENT | G63QQF2NOX | 1 | |
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| OCTISALATE | ACTIVE INGREDIENT | 4X49Y0596W | 1 | |
| AVOBENZONE | ACTIVE MOIETY | G63QQF2NOX | 1 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| OCTISALATE | ACTIVE MOIETY | 4X49Y0596W | 1 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 1 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| BUTYLPARABEN | INACTIVE INGREDIENT | 3QPI1U3FV8 | 1 | |
| CARBOMER HOMOPOLYMER TYPE C | INACTIVE INGREDIENT | 4Q93RCW27E | 1 | |
| CETOSTEARYL ALCOHOL | INACTIVE INGREDIENT | 2DMT128M1S | 1 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| CYCLOMETHICONE 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| CYCLOMETHICONE 6 | INACTIVE INGREDIENT | XHK3U310BA | 1 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| ETHYLPARABEN | INACTIVE INGREDIENT | 14255EXE39 | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| ISOBUTYLPARABEN | INACTIVE INGREDIENT | 0QQJ25X58G | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 1 | |
| POTASSIUM HYDROXIDE | INACTIVE INGREDIENT | WZH3C48M4T | 1 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| SHEA BUTTER | INACTIVE INGREDIENT | K49155WL9Y | 1 | |
| SODIUM ASCORBYL PHOSPHATE | INACTIVE INGREDIENT | 836SJG51DR | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- No7 Lifting and Firming Day Sunscreen SPF 8
- Octinoxate, Avobenzone and Octisalate
- OCTINOXATE
- AVOBENZONE
- OCTISALATE
- WATER
- GLYCERIN
- DIMETHICONE
- SHEA BUTTER
- CETOSTEARYL ALCOHOL
- CYCLOMETHICONE 5
- CYCLOMETHICONE 6
- POTASSIUM SORBATE
- BUTYLENE GLYCOL
- METHYLPARABEN
- SODIUM ASCORBYL PHOSPHATE
- ETHYLPARABEN
- CITRIC ACID MONOHYDRATE
- POTASSIUM HYDROXIDE
- CARBOMER HOMOPOLYMER TYPE C
- POLYSORBATE 20
- BUTYLATED HYDROXYTOLUENE
- PHENOXYETHANOL
- BUTYLPARABEN
- PROPYLPARABEN
- ISOBUTYLPARABEN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 11489-064 | 11489-064-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / ORAL | 269 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | POWDER, FOR SUSPENSION / ORAL | 1.3 mg/5ml | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRADERMAL | 1 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | EMULSION / TOPICAL | 2 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAVENOUS | 5 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ENEMA / RECTAL | 0.02 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / RECTAL | 6.67 %w/v | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | POWDER, FOR SUSPENSION / ORAL | 19 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, COATED / ORAL | 14.21 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, FILM COATED / ORAL | 42 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL / TOPICAL | 2.5 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SHAMPOO / TOPICAL | 17 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SPRAY / TOPICAL | 3 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SOFT TISSUE | ADJ PH | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ELIXIR / ORAL | 200 mg | ||
| ETHYLPARABEN | ETHYLPARABEN | 14255EXE39 | SOLUTION / ORAL | 14 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAVENOUS | 45 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / INTRAVENOUS | 0.02 %w/v | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CREAM / TOPICAL | 6 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | SPRAY / TOPICAL | 1 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SHAMPOO, SUSPENSION / TOPICAL | 0.25 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM, AUGMENTED / TOPICAL | 55 mg | ||
| CARBOMER HOMOPOLYMER TYPE C | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | 4Q93RCW27E | CREAM / TOPICAL | 103 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / IONTOPHORESIS | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / OPHTHALMIC | 0.05 %w/w | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | CREAM / TOPICAL | 0.4 %w/w | ||
| CARBOMER HOMOPOLYMER TYPE C | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | 4Q93RCW27E | GEL / OPHTHALMIC | 4 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GEL, METERED / TOPICAL | 4 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAMUSCULAR | 0.13 %w/v | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | INJECTION / INTRAVENOUS | 30 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / ORAL | 1 mg/1ml | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / RECTAL | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION/ DROPS / OPHTHALMIC | 0.05 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | PASTE / ORAL | 48 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / INTRAMUSCULAR | 0.02 %w/v | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | CAPSULE / ORAL | 563 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAMUSCULAR | 0.05 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | PASTE, DENTIFRICE / DENTAL | 0.05 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / TOPICAL | 17 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | PASTE, DENTIFRICE / DENTAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / TOPICAL | 0.8 %w/w | ||
| CARBOMER HOMOPOLYMER TYPE C | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | 4Q93RCW27E | GEL / TOPICAL | 85 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | SUPPOSITORY / VAGINAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 70998b82-8fab-4224-b366-065e62fe4a5c | 95401f03-10db-4e51-82b7-da10d867922e | 2010-12-06 | Warnings | 70998b82-8fab-4224-b366-065e62fe4a5c 95401f03-10db-4e51-82b7-da10d867922e |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.